No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
2024's 'Biggest Loses' That Could See Reversal in 2025
Express News | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Inhbe for the Treatment of Obesity
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,486, According to a Recent SEC Filing
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80
Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)